Key facts
- Link Cell Therapies’s last known valuation is $110.5M (Dec 2025).
- It has raised $72.0M; the latest was Early Stage VC ($60.0M) in Dec 2025.
- Notable investors include Wing Venture Capital, Johnson & Johnson JJDC, Samsara BioCapital, Bristol-Myers Squibb, Kyowa Kirin — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Link Cell Therapies
- ·The full record, as it builds
Funding rounds
No funding rounds for Link Cell Therapies are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Link Cell Therapies
Developer of cell therapies designed to help doctors detect solid cancer tumors. The company offers cancer cell therapy and the development of safe and effective CAR T agents, and an advanced suite of exciting therapeutic programs, enabling cancer patients with cancer indications, including solid tumors and certain haematologic cancers and helping to kill tumor cells while sparing healthy tissue.
- Sector
- Healthcare
- HQ
- South San Francisco, CA, United States
- Founded
- 2022
- Employees
- 23
- Website
- linkcelltx.com/
- Ownership
- Privately Held (backing)
Link Cell Therapies doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Link Cell Therapies shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Link Cell Therapies in its N-PORT filings yet. We sweep new filings monthly.